Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The EMERGE Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven mantle cell lymphoma~* Patients must have documents relapsed, refractory or PD after treatment with bortezomib~* Must have measureable disease on cross sectional imaging by CT~* Eastern Cooperative Oncology Group (ECOG) performance score 0,1 or 2~* Willing to follow pregnancy precautions~Exclusion Criteria:~* Any of the following laboratory abnormalities~  * Absolute neutrophil count (ANC) \< 1,500 cells/mm3 (1.5 x 109/L)~ * Platelet count \< 60,000/mm3 (60 x 109/L)~ * Serum aspartate transaminase/Serum glutamic oxaloacetic transaminase(AST/SGOT) or alanine transaminase/Serum glutamic pyruvic transaminase (ALT/SGPT) \> 3.0 x upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma.~ * Serum total bilirubin \> 1.5 x ULN, except in cases of Gilbert's Syndrome and documented liver involvement by lymphoma.~ * Calculated creatinine clearance (Cockcroft-Gault formula) of \< 30 mL /min~ * Patients who are candidates for high dose chemotherapy/allogeneic stem cell transplant are not eligible~ * History of active central nervous system (CNS) lymphoma within the previous 3 months~ * Subjects not willing or unable to take deep vein thrombosis (DVT) prophylaxis~ * Prior history of malignancies, other than MCL, unless the patient has been free of the disease for ≥ 3 years~ * Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but \< 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).